Peter Neupert - Laboratory Lead Independent Director
| LH Stock | USD 233.63 2.15 0.91% |
Director
Mr. Peter M. Neupert is Independent Director of the Company. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporationrationrate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the Presidents Information Technology Advisory Committee, cochairing the Health Information Technology Subcommittee and helping to drive the Revolutionizing Health Care Through Information Technology report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert is also a Director of Clinithink Ltd, Adaptive Biotechnologies, Inc., Navigating Cancer Inc., and higi SH Holdings Inc. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc. from August 2013 to January 2014 and Freedom Innovations LLC from May 2013 to April 2016. He serves as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicines Roundtable on Value ScienceDriven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. since 2019.
| Age | 65 |
| Tenure | 6 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0405 % which means that for every $100 of assets, it generated a profit of $0.0405. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0936 %, which means that it produced $0.0936 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Laboratory's Return On Tangible Assets are decreasing as compared to previous years. The Laboratory's current Return On Equity is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Laboratory's Other Current Assets are increasing as compared to previous years. The Laboratory's current Total Current Assets is estimated to increase to about 5 B, while Intangible Assets are projected to decrease to under 2.1 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frank DAmelio | Humana Inc | 63 | |
| Linda Baddour | Waters | 62 | |
| Marissa Peterson | Humana Inc | 58 | |
| Wright Lassiter | Quest Diagnostics Incorporated | 57 | |
| Maria Singer | Universal Health Services | 46 | |
| Warren Nimetz | Universal Health Services | 64 | |
| Christopher Kuebler | Waters | 66 | |
| David Feinberg | Humana Inc | 58 | |
| Gary Hendrickson | Waters | 64 | |
| Michael Berendt | Waters | 71 | |
| Frank Bisignano | Humana Inc | 62 | |
| Karen Katz | Humana Inc | 64 | |
| Timothy Ring | Quest Diagnostics Incorporated | 63 | |
| Edward Conard | Waters | 63 | |
| Gail Wilensky | Quest Diagnostics Incorporated | 76 | |
| Laurie Glimcher | Waters | 66 | |
| Thomas Salice | Waters | 61 | |
| Caspar Tudor | Waters | N/A | |
| Helen Torley | Quest Diagnostics Incorporated | 58 | |
| David Jones | Humana Inc | 71 | |
| Gary Pfeiffer | Quest Diagnostics Incorporated | 70 | |
Management Performance
| Return On Equity | 0.0936 | ||||
| Return On Asset | 0.0405 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Akinbolade Oyegunwa, Executive Officer | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Julia Wang, CFO VP | ||
| Jonathan DiVincenzo, Executive International | ||
| Kerrii Anderson, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Enterprise VP | ||
| John Treadwell, Vice Initiatives | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| JeanLuc Belingard, Independent Director | ||
| Sandra JD, Chief VP | ||
| Akinbolade MBA, Executive Officer | ||
| Kathryn Wengel, Independent Director | ||
| Peter Neupert, Lead Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| Richelle Parham, Independent Director | ||
| Robert Williams, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Garheng Kong, Independent Director | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0936 | ||||
| Return On Asset | 0.0405 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 25.82 B | ||||
| Shares Outstanding | 83.7 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 95.98 % | ||||
| Number Of Shares Shorted | 1.85 M | ||||
| Price To Earning | 12.69 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 8.85 | Revenue Per Share | Quarterly Revenue Growth 0.098 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.